Virtual meeting
Via Zoom
Description
As part of the twice-monthly SUD Care Continuum ECHO® series, Michael Lynch, MD, FACMT, will develop interdisciplinary strategies for identifying and responding to emerging drug supply adulterants such as medetomidine across clinical and harm reduction settings, and describe the emerging role of medetomidine in the illicit drug supply, including its pharmacologic effects and associated clinical risks. He will also apply clinical approaches to recognizing and managing suspected medetomidine exposure, including overdose response, withdrawal considerations, and linkage to ongoing care. The didactic will be followed by a de-identified patient case presentation from an ECHO® participant and recommendations from the panel of experts and attendees.
The Substance Use Disorder Care Continuum ECHO® (SUD Care Continuum ECHO®) series offers training and support in addiction treatment, with a focus on supporting front line addiction treatment workforce. This includes health providers in Acute Treatment Services (ATS), Crisis Stabilization Services (CSS), Transitional Support Services (TSS), Opioid Treatment Programs (OTP), long-term residential program, sober and recovery homes, primary care, and psychiatry. This free, case-based tele-mentoring program is designed to increase the capacity of health care providers to implement high-quality and evidence-based addiction treatment.
Intended audience
Providers, nurses, social workers, psychologists, peer supports, other clinical staff, and non-clinicians.
Speakers
Michael Lynch, MD, FACMT
Michael Lynch, MD, FACMT, is an associate professor of emergency medicine at the University of Pittsburgh and an attending emergency physician and medical toxicologist at UPMC. He serves as medical director of the Pittsburgh Poison Center and medical director of substance use disorder services at UPMC Health Plan.
Objectives
Following this training, participants will have the knowledge to:
1. Develop interdisciplinary strategies for identifying and responding to emerging drug supply adulterants such as medetomidine across clinical and harm reduction settings.
2. Describe the emerging role of medetomidine in the illicit drug supply, including its pharmacologic effects and associated clinical risks.
3. Apply clinical approaches to recognizing and managing suspected medetomidine exposure, including overdose response, withdrawal considerations, and linkage to ongoing care.
Sponsored by
Massachusetts Department of Public Health, Bureau of Substance Addiction Services (DPH/BSAS)
Accreditation information
Please read the Accreditation Information section of the training registration page for accreditation details and to learn about the requirements for receiving credit or a certificate of completion.
